**Response-Guided Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2**

Jean-Pierre Bronowicki, Jonathan McCone, Bruce R. Bacon, Savino Bruno, Michael P. Manns, Mark S. Sulkowski, Ira M. Jacobson, Rajender Reddy, Navdeep Boparai, Vilma Sniukiene, Clifford A. Brass, Janice K. Albrecht, Fred Poordad

*Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France; Gastroenterology/ Hepatology/Endoscopy Centers, Alexandria, VA, United States; Saint Louis University School of Medicine, St. Louis, MO, United States; University of Milan, Milan, Italy; Medical School of Hannover, Hannover, Germany; Johns Hopkins University School of Medicine, Baltimore, MD, United States; The Joan Sanford I. Weill Medical College of Cornell University, New York, NY, United States; University of Pennsylvania, Philadelphia, PA, United States; Mercy, Whitehouse Station, NJ, United States; Cedars Sinai Medical Center, Los Angeles, CA, United States.*

---

**Abstract**

Efficacy Results in SPRINT-2

- **SVR Rates in all randomized patients:**
  - 77% (185/241) in BOC RGT + BOC/PR48
  - 74% (116/156) in BOC RGT + BOC/P/R
  - 66% (91/137) in BOC RGT + BOC/P/R48

- **SVR Rates in treatment-naïve patients:**
  - 83% (145/174) in BOC RGT + BOC/PR48
  - 79% (114/144) in BOC RGT + BOC/P/R
  - 71% (91/129) in BOC RGT + BOC/P/R48

- **SVR Rates in treatment-experienced patients:**
  - 68% (40/59) in BOC RGT + BOC/PR48
  - 61% (32/52) in BOC RGT + BOC/P/R
  - 58% (30/52) in BOC RGT + BOC/P/R48

**Discussion**

- **SVR rates based on HCV-RNA levels:**
  - **Non-Black patients:**
    - 96% for those in the highest quartile of HCV-RNA levels at weeks 8–24
    - 83% for those in the lower three quartiles of HCV-RNA levels at weeks 8–24
  - **Black patients:**
    - 60% for those in the highest quartile of HCV-RNA levels at weeks 8–24
    - 45% for those in the lower three quartiles of HCV-RNA levels at weeks 8–24

**Methods**

- **Study design:**
  - **Phase 3 study of treatment-naïve CHC genotype 1 adults (SPRINT-2)**
  - **170 centers worldwide**

- **Inclusion criteria:**
  - Age 18–75 years
  - BMI ≤ 40 kg/m²
  - Genotype 1a or 1b
  - HCV-RNA level > 400,000 IU/mL
  - No previous treatment with peginterferon alfa-2b/ribavirin

- **Exclusion criteria:**
  - Decompensated liver disease
  - Active alcohol use
  - Current pregnancy or lactation
  - HIV infection

- **Randomization:**
  - 1:1 ratio to BOC RGT + BOC/PR48 or BOC RGT + BOC/P/R

- **Treatment groups:**
  - **BOC RGT + BOC/PR48**
  - **BOC RGT + BOC/P/R**
  - **BOC RGT + BOC/P/R48**

- **Dosing regimen:**
  - Peginterferon alfa-2b (P) administered subcutaneously at 1.5 μg/kg once weekly; ribavirin (R) using weight-based dosing.

- **Follow-up:**
  - Week 8, 12, 24, and 48

- **Virologic response:**
  - SVR achieved if HCV-RNA > LLDD at weeks 24, 28, and 48

- **Statistical analysis:**
  - Log-rank test for time-to-event endpoints
  - Chi-square test for categorical variables

**Results**

- **SVR rates in all randomized patients:**
  - 77% (185/241) in BOC RGT + BOC/PR48
  - 74% (116/156) in BOC RGT + BOC/P/R
  - 66% (91/137) in BOC RGT + BOC/P/R48

- **SVR rates in treatment-naïve patients:**
  - 83% (145/174) in BOC RGT + BOC/PR48
  - 79% (114/144) in BOC RGT + BOC/P/R
  - 71% (91/129) in BOC RGT + BOC/P/R48

- **SVR rates in treatment-experienced patients:**
  - 68% (40/59) in BOC RGT + BOC/PR48
  - 61% (32/52) in BOC RGT + BOC/P/R
  - 58% (30/52) in BOC RGT + BOC/P/R48

- **SVR rates based on HCV-RNA levels:**
  - **Non-Black patients:**
    - 96% for those in the highest quartile of HCV-RNA levels at weeks 8–24
    - 83% for those in the lower three quartiles of HCV-RNA levels at weeks 8–24
  - **Black patients:**
    - 60% for those in the highest quartile of HCV-RNA levels at weeks 8–24
    - 45% for those in the lower three quartiles of HCV-RNA levels at weeks 8–24

**Conclusion**

- **RGT paradigm yielded high responses equal to those with the BOC/PR48 regimen**
  - SVR rates for treatment-naïve patients with CHC genotype 1 who received BOC RGT + BOC/PR48 were similar to those with BOC RGT + BOC/P/R48 or BOC RGT + BOC/P/R.

**Disclosure**


**Acknowledgements**

- The authors thank the patients and the investigators who contributed to this study. They also thank the study staff at each center who made this study possible, including R. Bailey, M. Bilodeau, C. Cooper, S.V. Feinman, F. Anderson, R. Bailey, M. Bilodeau, C. Cooper, S.V. Feinman.